Estrogen priming before progestin therapy in advanced breast cancer

Shaun S J Hung, Dawn East, Charles Vogel, Grace Wang, Susan G. Hilsenbeck

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We conducted a prospective trial of sequential administration of oral ethinyl estradiol (EE) with medroxyprogesterone acetate (MPA) in postmenopausal women with estrogen receptorpositive breast carcinoma that had not been treated with additive hormonal therapy. A 14-day treatment cycle consisted of 1.0 mg/day EE on days 1 and 2, 400 mg/day MPA on days 3 through 12, and no treatment on days 13 and 14. Seven (44%) of the 16 evaluable patients had partial responses, but no complete responses were observed. The median duration of response was 7.6 months. Fifty-three percent of the patients experienced therapy-related complications including two cases of thromboembolism. Estrogen priming before progestin therapy as used in this study cannot be recommended for routine use because the response rate does not seem to be better than that of monohormonal therapy in the face of a high incidence of complications.

Original languageEnglish
Pages (from-to)87-94
Number of pages8
JournalBreast Disease
Volume3
Issue number2
StatePublished - Jul 1 1990

Fingerprint

Progestins
Estrogens
Breast Neoplasms
Medroxyprogesterone Acetate
Ethinyl Estradiol
Therapeutics
Thromboembolism
Oral Administration
Incidence

Keywords

  • breast carcinoma
  • ethinyl estradiol
  • medroxyprogesterone acetate

ASJC Scopus subject areas

  • Surgery

Cite this

Hung, S. S. J., East, D., Vogel, C., Wang, G., & Hilsenbeck, S. G. (1990). Estrogen priming before progestin therapy in advanced breast cancer. Breast Disease, 3(2), 87-94.

Estrogen priming before progestin therapy in advanced breast cancer. / Hung, Shaun S J; East, Dawn; Vogel, Charles; Wang, Grace; Hilsenbeck, Susan G.

In: Breast Disease, Vol. 3, No. 2, 01.07.1990, p. 87-94.

Research output: Contribution to journalArticle

Hung, SSJ, East, D, Vogel, C, Wang, G & Hilsenbeck, SG 1990, 'Estrogen priming before progestin therapy in advanced breast cancer', Breast Disease, vol. 3, no. 2, pp. 87-94.
Hung SSJ, East D, Vogel C, Wang G, Hilsenbeck SG. Estrogen priming before progestin therapy in advanced breast cancer. Breast Disease. 1990 Jul 1;3(2):87-94.
Hung, Shaun S J ; East, Dawn ; Vogel, Charles ; Wang, Grace ; Hilsenbeck, Susan G. / Estrogen priming before progestin therapy in advanced breast cancer. In: Breast Disease. 1990 ; Vol. 3, No. 2. pp. 87-94.
@article{985d28ee5b244c12be2571985a44ff4e,
title = "Estrogen priming before progestin therapy in advanced breast cancer",
abstract = "We conducted a prospective trial of sequential administration of oral ethinyl estradiol (EE) with medroxyprogesterone acetate (MPA) in postmenopausal women with estrogen receptorpositive breast carcinoma that had not been treated with additive hormonal therapy. A 14-day treatment cycle consisted of 1.0 mg/day EE on days 1 and 2, 400 mg/day MPA on days 3 through 12, and no treatment on days 13 and 14. Seven (44{\%}) of the 16 evaluable patients had partial responses, but no complete responses were observed. The median duration of response was 7.6 months. Fifty-three percent of the patients experienced therapy-related complications including two cases of thromboembolism. Estrogen priming before progestin therapy as used in this study cannot be recommended for routine use because the response rate does not seem to be better than that of monohormonal therapy in the face of a high incidence of complications.",
keywords = "breast carcinoma, ethinyl estradiol, medroxyprogesterone acetate",
author = "Hung, {Shaun S J} and Dawn East and Charles Vogel and Grace Wang and Hilsenbeck, {Susan G.}",
year = "1990",
month = "7",
day = "1",
language = "English",
volume = "3",
pages = "87--94",
journal = "Breast Disease",
issn = "0888-6008",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Estrogen priming before progestin therapy in advanced breast cancer

AU - Hung, Shaun S J

AU - East, Dawn

AU - Vogel, Charles

AU - Wang, Grace

AU - Hilsenbeck, Susan G.

PY - 1990/7/1

Y1 - 1990/7/1

N2 - We conducted a prospective trial of sequential administration of oral ethinyl estradiol (EE) with medroxyprogesterone acetate (MPA) in postmenopausal women with estrogen receptorpositive breast carcinoma that had not been treated with additive hormonal therapy. A 14-day treatment cycle consisted of 1.0 mg/day EE on days 1 and 2, 400 mg/day MPA on days 3 through 12, and no treatment on days 13 and 14. Seven (44%) of the 16 evaluable patients had partial responses, but no complete responses were observed. The median duration of response was 7.6 months. Fifty-three percent of the patients experienced therapy-related complications including two cases of thromboembolism. Estrogen priming before progestin therapy as used in this study cannot be recommended for routine use because the response rate does not seem to be better than that of monohormonal therapy in the face of a high incidence of complications.

AB - We conducted a prospective trial of sequential administration of oral ethinyl estradiol (EE) with medroxyprogesterone acetate (MPA) in postmenopausal women with estrogen receptorpositive breast carcinoma that had not been treated with additive hormonal therapy. A 14-day treatment cycle consisted of 1.0 mg/day EE on days 1 and 2, 400 mg/day MPA on days 3 through 12, and no treatment on days 13 and 14. Seven (44%) of the 16 evaluable patients had partial responses, but no complete responses were observed. The median duration of response was 7.6 months. Fifty-three percent of the patients experienced therapy-related complications including two cases of thromboembolism. Estrogen priming before progestin therapy as used in this study cannot be recommended for routine use because the response rate does not seem to be better than that of monohormonal therapy in the face of a high incidence of complications.

KW - breast carcinoma

KW - ethinyl estradiol

KW - medroxyprogesterone acetate

UR - http://www.scopus.com/inward/record.url?scp=0025164621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025164621&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 87

EP - 94

JO - Breast Disease

JF - Breast Disease

SN - 0888-6008

IS - 2

ER -